Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 5/20 | 0.60 |
| ▸ | KDR | P35968 | 4/20 | 0.60 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.54 |
| ▸ | PDE10A | Q9Y233 | 10/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.45 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | KIF5B | P33176 | 1/20 | 0.45 |
| ▸ | GAK | O14976 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6098070 | 1.00 | FLT1 (0.60) | FLT1KDRFGFR1PDE10APDPK1 | |
| SCHEMBL2206398 | 0.87 | PDE10A (0.54) | FLT1KDRPDE10A | |
| SCHEMBL16285128 | 0.84 | PDE10A (0.50) | FLT1KDRFGFR1PDE10A | |
| SCHEMBL4772499 | 0.83 | KDR (0.54) | FLT1KDRFGFR1PDE10APDPK1 | |
| SCHEMBL6096985 | 0.83 | KDR (0.60) | FLT1KDRFGFR1PDE10APDPK1 | |
| SCHEMBL5015469 | 0.80 | KDR (0.57) | FLT1KDRFGFR1PDE10APDPK1 | |
| SCHEMBL6096613 | 0.79 | FLT1 (0.49) | FLT1KDRFGFR1PDE10ARET | |
| SCHEMBL6097961 | 0.79 | FLT1 (0.49) | FLT1KDRFGFR1PDE10ARET | |
| SCHEMBL5025607 | 0.79 | PDE10A (0.55) | PDE10APDPK1EGFR | |
| SCHEMBL6096514 | 0.79 | FLT1 (0.55) | FLT1KDRFGFR1PDE10AFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1991531-A1 | CINNOLINE AND QUINOXALINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-12-13 | — | — | US | disclosed |
| WO-2007100880-A1 | CINNOLINE AND QUINAZOLINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE7B, PDE10A | FLT1 4564/4885KDR 4714/4885FGFR1 2917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.